QNRX

Quoin Pharmaceuticals Ltd ADR

4.01

Oct 26 • 3:59 PM ET -0.01 (-0.25%)

4.01

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: AZTR PVLA ABEO DRMA KRYS TTRX VRCA ACRS ARQT CUVL

Scroll to Statements

Index	-
Market Cap	8.06M
Enterprise Value	-2.74M
Income	-18.79M
Sales	0.00M
Book/sh	1.96
Cash/sh	5.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	4
IPO	Jul 29, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.05
P/C	0.75
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.76
Current Ratio	1.76
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-14.93
EPS next Y	-2.71
EPS next Q	-1.52
EPS this Y	58.95%
EPS next Y	55.45%
EPS next 5Y	51.90%
EPS past 3/5Y	2.37% 61.71%
Sales past 3/5Y	- -
EPS Y/Y TTM	98.98%
Sales Y/Y TTM	-
EPS Q/Q	98.79%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	-18.01% -

Insider Own	-
Insider Trans	-
Inst Own	70.47%
Inst Trans	2.92%
ROA	-179.96%
ROE	-579.57%
ROIC	-477.79%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.01%
SMA50	-26.94%
SMA200	-35.30%
Trades

Shs Outstand	2.01M
Shs Float	-
Short Float	-
Short Ratio	0.12
Short Interest	0.07M
52W High	23.50 -82.94%
52W Low	3.25 23.38%
Volatility	4.65% 9.18%
ATR (14)	0.39
RSI (14)	30.77
Beta	1.74
Rel Volume	0.03
Avg Volume	536.54K
Volume	14,892

Perf Week	0.75%
Perf Month	-37.64%
Perf Quarter	-4.52%
Perf Half Y	-26.56%
Perf YTD	-72.21%
Perf Year	-69.03%
Perf 3Y	-97.34%
Perf 5Y	-99.99%
Perf 10Y	-100.00%
Recom	1.00
Target Price	21.57
Prev Close	4.02
Price	4.01
Change %	-0.25%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-19-26	Initiated	Canaccord Genuity	Buy	$18
Oct-12-26	Initiated	BTIG Research	Buy	$14
Sep-23-26	Initiated	Lake Street	Buy	$20

Oct-20-26 06:30AM	Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy (GlobeNewswire)
Oct-14-26 06:30AM	Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome (GlobeNewswire)
Oct-06-26 06:30AM	Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy (GlobeNewswire)
Sep-24-26 09:50AM	Four Small-Cap Stocks Report New Developments (CHGA, QNRX, MYSE, LNKS) (FinanceWire) -5.48%
Sep-22-26 08:30AM	Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome (GlobeNewswire)
08:30AM	Loading…
Sep-10-26 08:30AM	Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU (GlobeNewswire)
Sep-08-26 02:12PM	CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome (GlobeNewswire)
01:28PM	Quoin in line for second priority review voucher if rare paediatric drug approved (Pharmaceutical Technology)
01:28PM	Quoin in line for priority review voucher if rare paediatric drug approved (Pharmaceutical Technology)
08:30AM	Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome (GlobeNewswire)
Aug-28-26 06:00AM	Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome (GlobeNewswire) +18.72%
06:00AM	Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million (GlobeNewswire)
Aug-14-26 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire) -15.87%
Aug-07-26 08:30AM	Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026 (GlobeNewswire)
Jul-09-26 08:30AM	Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome (GlobeNewswire)
08:30AM	Loading…
Jun-30-26 08:30AM	Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome (GlobeNewswire) +6.37%
Jun-23-26 08:30AM	Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI as the Proposed Brand Name for QRX003 for Netherton Syndrome (GlobeNewswire) -26.30%
Jun-18-26 08:30AM	Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003 (GlobeNewswire)
Jun-16-26 08:30AM	Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program (GlobeNewswire)
Jun-04-26 08:30AM	Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome (GlobeNewswire)
Jun-02-26 08:30AM	Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome (GlobeNewswire)
May-07-26 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results (GlobeNewswire)
Apr-30-26 08:30AM	Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026 (GlobeNewswire) +9.27%
Apr-28-26 12:02PM	CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs (GlobeNewswire)
08:30AM	Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs (GlobeNewswire)
Mar-26-26 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire) -18.39%
Mar-25-26 08:30AM	Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome (GlobeNewswire) +15.88%
Mar-19-26 08:30AM	Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 (GlobeNewswire) +5.36%
Mar-11-26 08:30AM	Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome (GlobeNewswire)
Feb-26-26 08:30AM	NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome (GlobeNewswire)
08:30AM	Loading…
Jan-27-26 08:30AM	Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome (GlobeNewswire)
Jan-20-26 08:30AM	Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome (GlobeNewswire)
Nov-11-25 08:30AM	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies (GlobeNewswire) +41.40%
Nov-06-25 08:30AM	Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results (GlobeNewswire) -11.19%
Oct-30-25 08:30AM	Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025 (GlobeNewswire) -7.15%
Oct-28-25 08:30AM	Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month 'Whole Body' Data Update from Ongoing Study (GlobeNewswire)
Oct-21-25 08:30AM	Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome (GlobeNewswire)
Oct-10-25 09:24AM	Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million (GlobeNewswire) +151.23%
Sep-09-25 08:30AM	Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome (GlobeNewswire)
Aug-21-25 08:30AM	Quoin Pharmaceuticals' NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome (GlobeNewswire)
Aug-18-25 08:30AM	Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy (GlobeNewswire)
Aug-12-25 08:30AM	Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton (GlobeNewswire)
Aug-07-25 08:30AM	Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire) -6.24%
Jul-31-25 08:30AM	Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025 (GlobeNewswire) -12.36%
Jul-29-25 08:30AM	Quoin Pharmaceuticals Provides Product Portfolio Update (GlobeNewswire)
Jun-26-25 08:30AM	Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases (GlobeNewswire)
Jun-24-25 08:30AM	Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome (GlobeNewswire)
May-22-25 07:30AM	Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study (GlobeNewswire)
May-20-25 07:30AM	Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome (GlobeNewswire) +6.01%
May-14-25 07:30AM	Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study (GlobeNewswire) +20.28%
May-13-25 08:00AM	Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results (GlobeNewswire)
May-06-25 08:00AM	Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025 (GlobeNewswire)
Apr-30-25 07:30AM	Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire)
Apr-10-25 07:30AM	Quoin Pharmaceuticals Releases Second Episode of its Living with Netherton Series, as part of its ongoing NETHERTON NOW awareness campaign (GlobeNewswire) -20.32%
Apr-02-25 07:30AM	Quoin Pharmaceuticals Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient (GlobeNewswire) +38.23%
Mar-25-25 07:30AM	Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases (GlobeNewswire)
Mar-13-25 07:30AM	Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Mar-06-25 08:00AM	Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025 (GlobeNewswire) -7.35%
Mar-04-25 07:30AM	Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications (GlobeNewswire)
Feb-27-25 07:30AM	Quoin Pharmaceuticals Announces Highly Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study (GlobeNewswire) +15.40%
Feb-25-25 07:30AM	Quoin Pharmaceuticals Launches First Episode of "NETHERTON NOW" Video Series to Raise Awareness for Netherton Syndrome (GlobeNewswire)
Feb-04-25 07:30AM	Quoin Pharmaceuticals Launches 'NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure (GlobeNewswire)
Jan-23-25 08:30AM	Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome (GlobeNewswire) -30.22%
05:30AM	Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies (ACCESSWIRE)
Jan-14-25 08:30AM	Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study (GlobeNewswire)
Jan-07-25 02:29PM	PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials (GlobeNewswire)
Jan-06-25 08:30AM	Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study (GlobeNewswire)
Dec-20-24 09:20AM	Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering (GlobeNewswire) -12.03%
Dec-19-24 08:00AM	Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study (GlobeNewswire) +14.99%
Dec-18-24 08:18AM	Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies (GlobeNewswire) -6.65%
Nov-07-24 08:00AM	Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 08:00AM	Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient (GlobeNewswire)
Oct-31-24 04:05PM	Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024 (GlobeNewswire) -7.78%
Oct-22-24 08:00AM	Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome (GlobeNewswire) -13.03%
Sep-09-24 08:30AM	Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO (GlobeNewswire) +24.71%
Aug-08-24 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results (GlobeNewswire) -7.17%
Aug-06-24 05:00AM	Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome (GlobeNewswire)
Aug-01-24 04:10PM	Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
Jun-27-24 08:00AM	Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome (GlobeNewswire)
Jun-25-24 04:05PM	Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference (GlobeNewswire)
Jun-12-24 08:00AM	Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland (GlobeNewswire)
May-09-24 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 04:10PM	Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire) +6.34%
Mar-15-24 10:52AM	Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 04:05PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results (GlobeNewswire) -13.79%
Mar-07-24 04:05PM	Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET (GlobeNewswire) -8.47%
Mar-05-24 08:34AM	Why Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today? (InvestorPlace) -48.28%
08:00AM	Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering (GlobeNewswire)
Mar-04-24 08:00AM	Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies (GlobeNewswire)
Feb-14-24 09:00AM	Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome (ACCESSWIRE)
Feb-08-24 08:00AM	Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product (GlobeNewswire)
Dec-13-23 08:30AM	Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome (GlobeNewswire)
Nov-10-23 12:19PM	Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 05:46PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire) -8.26%
Nov-03-23 08:41AM	Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET (GlobeNewswire)
Oct-24-23 09:32AM	REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome (GlobeNewswire) +8.04%
08:28AM	Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome (GlobeNewswire)
Oct-02-23 12:25PM	QNRX: Positive Early Clinical Data, Moving QRX003 Through Multiple Trials (Zacks)
Aug-09-23 08:30AM	Quoin Pharmaceuticals' Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for Shareholders (NewMediaWire)
Aug-02-23 04:45PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results (GlobeNewswire) -10.67% +6.26%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carter Denise P.	Chief Operating Officer	Aug 31 '26	Buy	4.88	20,490	99,991	37,709	Sep 01 09:40 PM
Myers Michael	Chief Executive Officer	Aug 31 '26	Buy	4.88	20,490	99,991	37,713	Sep 01 09:39 PM
Lawlor Sally Bridget	Chief Financial Officer	Aug 31 '26	Buy	4.88	10,244	49,991	10,684	Sep 01 09:39 PM
Culverwell Anthony James	Director	Aug 31 '26	Buy	4.88	6,146	29,992	40,364	Sep 01 09:38 PM

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Co-FounderDr. Michael Myers Ph.D.

Co-FounderMs. Denise Carter

Chief Financial OfficerMs. Sally Lawlor

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QNRX

Quoin Pharmaceuticals Ltd ADR

Upgrade your Finviz experience